吉林医学
吉林醫學
길림의학
JILIN MEDICAL JOURANL
2013年
8期
1432-1433
,共2页
再生障碍性贫血%环孢素A
再生障礙性貧血%環孢素A
재생장애성빈혈%배포소A
Aplastic anemia%Cyclosporine A
目的:探讨环孢素A治疗再生障碍性贫血的临床疗效.方法:选择118例再生障碍性贫血患者,随机分为治疗组和对照组各59例,其中治疗组采用用环孢素A进行治疗,对照组采用司坦唑醇治疗,治疗后,比较两组患者的临床疗效、血液指标变化情况和不良反应发生情况.结果:治疗组的总有效率为89.83%,显著高于对照组的总有效率76.27%,差异有统计学意义(P<0.05);两组患者的白细胞数、血红蛋白量和血小板数均较治疗前显著升高,且治疗后治疗组较对照组均显著高于对照组(P<0.05);治疗组的不良反应率为32.20%,高于对照组的27.12%,差异无统计学意义(P>0.05).结论:采用环孢素A治疗再生障碍性贫血的临床疗效较佳,不良反应发生率略高,但均为一过性.
目的:探討環孢素A治療再生障礙性貧血的臨床療效.方法:選擇118例再生障礙性貧血患者,隨機分為治療組和對照組各59例,其中治療組採用用環孢素A進行治療,對照組採用司坦唑醇治療,治療後,比較兩組患者的臨床療效、血液指標變化情況和不良反應髮生情況.結果:治療組的總有效率為89.83%,顯著高于對照組的總有效率76.27%,差異有統計學意義(P<0.05);兩組患者的白細胞數、血紅蛋白量和血小闆數均較治療前顯著升高,且治療後治療組較對照組均顯著高于對照組(P<0.05);治療組的不良反應率為32.20%,高于對照組的27.12%,差異無統計學意義(P>0.05).結論:採用環孢素A治療再生障礙性貧血的臨床療效較佳,不良反應髮生率略高,但均為一過性.
목적:탐토배포소A치료재생장애성빈혈적림상료효.방법:선택118례재생장애성빈혈환자,수궤분위치료조화대조조각59례,기중치료조채용용배포소A진행치료,대조조채용사탄서순치료,치료후,비교량조환자적림상료효、혈액지표변화정황화불량반응발생정황.결과:치료조적총유효솔위89.83%,현저고우대조조적총유효솔76.27%,차이유통계학의의(P<0.05);량조환자적백세포수、혈홍단백량화혈소판수균교치료전현저승고,차치료후치료조교대조조균현저고우대조조(P<0.05);치료조적불량반응솔위32.20%,고우대조조적27.12%,차이무통계학의의(P>0.05).결론:채용배포소A치료재생장애성빈혈적림상료효교가,불량반응발생솔략고,단균위일과성.
Objective To investigate the clinical efficacy of cyclosporin A in the treatment of aplastic anemia.Methods 118 cases of aplastic anemia patients were randomly divided into the treatment group and the control group,and 59 cases in each group,in which the treatment group was treated with cyclosporine A treatment,and the control group using stanozolol treatment.After treatment,the clinical efficacy,blood indicators of changes in circumstances and adverse events between the two groups of patients were compared.Results The total effective rate of the treatment group was 89.83%,significantly higher than the total efficiency of 76.27%(P<0.05).The white blood cell count,hemoglobin and platelet count were significantly increased than before treatment,and after treatment,the treatment group compared with the control group,it was significantly higher(P<0.05).The adverse reaction rate of the treatment group was 32.20%,higher than 27.12%,but there was no significant difference(P>0.05). Conclusion The clinical efficacy of cyclosporine A in the treatment of aplastic anemia is better,and it is with a slightly higher incidence of adverse reactions,but it is transient.